Treatment Crossovers Did Not Affect Randomized Treatment Comparisons in the Mode Selection Trial (MOST)  by Hellkamp, Anne S. et al.
T
N
C
A
M
D
T
6
v
(
d
p
a
t
D
V
n
a
‡
i
H
L
M
m
c
M
c
a
Journal of the American College of Cardiology Vol. 47, No. 11, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PHeart Rhythm Disorders
reatment Crossovers Did
ot Affect Randomized Treatment
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OBJECTIVES We evaluated the impact of treatment crossovers on study results in the Mode Selection Trial
(MOST).
BACKGROUND The MOST study, a 2,010-patient, 6-year trial comparing dual-chamber pacing (DDDR)
and ventricular pacing (VVIR) in sinus node dysfunction, demonstrated no difference in death
or stroke and modest reductions in heart failure hospitalization (HFH) and atrial fibrillation
(AF) with DDDR pacing. However, a moderate proportion of VVIR-randomized patients
were temporarily or permanently crossed over to DDDR pacing.
METHODS Intent-to-treat (ITT) analyses compared treatment arms by randomized pacing mode.
On-treatment analyses used time-dependent covariates to account for all crossovers. All
analyses used Cox proportional hazards models and included covariates prespecified in the
study design: age, gender, Charlson index, and prior stroke, heart failure, myocardial
infarction, supraventricular tachyarrhythmia, and ventricular tachycardia or fibrillation.
RESULTS Of 996 VVIR-randomized patients, 375 (38%) were DDDR paced at some time, accounting
for 27% of follow-up days among all VVIR-randomized patients. Of 1,014 DDDR-
randomized patients, 53 (5%) were VVIR paced at some time, accounting for 1.5% of
follow-up days among all DDDR-randomized patients. On-treatment analyses showed slightly
lower hazard ratios favoring DDDR versus VVIR compared with ITT: death or stroke 0.88
(on-treatment) versus 0.91 (ITT); death 0.94 versus 0.95; stroke 0.74 versus 0.81; HFH 0.72
versus 0.73; and AF 0.72 versus 0.77. Interpretation of treatment effects was unchanged.
CONCLUSIONS Although treatment crossovers accounted for25% of follow-up time in the VVIR-randomized
group, this did not affect study results. End point comparisons between randomized modes are
accurate reflections of DDDR versus VVIR pacing in this study population. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.0692006;47:2260–6) © 2006 by the American College of Cardiology Foundation
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phe Mode Selection Trial (MOST) was a 2,010-patient,
-year trial comparing dual-chamber pacing (DDDR) and
entricular pacing (VVIR) in sinus node dysfunction (SND)
1). In the major intent-to-treat analyses, the MOST study
emonstrated no difference between pacing modes in the
rimary composite end point of all-cause death or stroke,
lthough significant reductions in heart failure hospitaliza-
ion (HFH) and atrial fibrillation (AF) were observed with
DDR pacing. However, a moderate proportion (38%) of
VIR-randomized patients were temporarily or perma-
ently crossed over to DDDR pacing. The purpose of this
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ccepted January 9, 2006.tudy was to assess the impact of these treatment crossovers
n the interpretation of the MOST study results.
Intent-to-treat analyses are the gold standard of clinical
rials. Randomization of treatment assignment ensures that the
reatment groups are similar in terms of relevant baseline
haracteristics, and that any difference in outcomes between
he groups can reasonably be attributed to the treatment.
owever, if a large proportion of patients discontinue treat-
ent or change to another treatment arm, it becomes more
ifficult to determine the existence and magnitude of treatment
ffect. On-treatment analyses address this problem by compar-
ng patients who received one treatment to patients who
eceived another, but because treatment assignment is no
onger completely random, results can be biased by any
ssociation between likelihood of treatment change and risk of
vent (e.g., if factors that make a patient more likely to change
reatment also make them more likely to have the event).
Crossovers may have affected the MOST study by making
utcomes in the two treatment arms more homogeneous than
hey were in reality. The VVIR arm as randomized was really
mix of VVIR-paced patients and patients who were DDDR-
aced during part of their follow-up. Therefore, where an
nderlying treatment effect exists, a comparison of randomized
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June 6, 2006:2260–6 Treatment Crossovers in the MOST Studyreatments might show a nonsignificant effect or might show a
ignificant effect but underestimate its size. Where no under-
ying treatment effect exists, crossovers would have no impact
n randomized mode comparisons.
ETHODS
he design and conduct of the MOST study have been
reviously described (1,2). Briefly, 2,010 patients with SND
ere randomized to DDDR or VVIR pacing at the time of
acemaker implantation. Patients were seen at 1, 3, and 6
onths after implant and every 6 months thereafter; median
ollow-up was 33 months. Because all patients received a
ual-chamber device, mode changes (crossovers) required only
rogramming changes. All mode changes were documented by
he sites and reported as part of the case report form. Deaths,
trokes, and first HFH were adjudicated by a clinical events
ommittee blinded to treatment. First documented episode of
F was adjudicated by an electrocardiographic core laboratory.
Although pacemakers could be programmed in a variety
f ways (e.g., DDIR, DDD, VVI), for the purposes of this
nalysis all dual-chamber or atrial pacing modes were
onsidered DDDR and all ventricular pacing modes were
onsidered VVIR.
Time in each mode for each patient was calculated from
ode change dates provided by the sites. For displaying
ime in each mode graphically, patients were classified for
ach month of follow-up by the mode in which they spent
he majority of that month. For the purpose of character-
zing crossover and noncrossover groups at baseline, patients
ere classified as DDDR (all patients randomized to
Abbreviations and Acronyms
AF  atrial fibrillation
CTOPP  Canadian Trial Of Physiologic Pacing
DDDR  dual-chamber pacing
HFH  heart failure hospitalization
MOST  Mode Selection Trial
PASE  Pacemaker Selection in the Elderly
SND  sinus node dysfunction
UKPACE  UK Pacing and Cardiovascular Events
VVIR  ventricular pacingFigure 1. Number of patients in each pacing mode by month after implDDR), VVIR-crossover (all VVIR-randomized patients
ho permanently crossed to DDDR or who spent at least
ne third of follow-up time in DDDR), and VVIR-no
rossover (all other VVIR-randomized patients). Continuous
aseline variables are summarized by group as median (25th,
5th), and categoric variables are summarized as percent
number). Baseline variables were compared between VVIR-
rossover and VVIR-no crossover groups using Wilcoxon rank
um tests for continuous variables and likelihood ratio chi-
quare tests for categoric variables.
Cox proportional hazards models (3) were used to examine
he association of pacing mode with event risk. Intent-to-treat
nalyses compared treatment arms according to randomized
acing mode. On-treatment analyses used a time-dependent
ovariate to account for all mode changes during follow-up.
hus, event-free follow-up time for a patient before any
rossover would be credited to the treatment arm to which the
atient was randomized, whereas at crossover, the patient
ould shift to the other arm. Some patients shifted between
acing modes multiple times. All Cox model treatment com-
arisons were adjusted for eight baseline covariates that were
respecified for secondary adjusted comparisons in the study
esign: age, gender, prior stroke, prior HF, prior myocardial
nfarction, Charlson comorbidity index (4), prior supraventric-
lar arrhythmia, and prior ventricular tachycardia or fibrilla-
ion. Relative risk for each event is presented as a hazard ratio
nd 95% confidence interval.
Event-free survival curves for groups defined by randomized
acing modes were generated using Kaplan-Meier estimates
5). For on-treatment event-free survival curves, event rate
alculations were modified by counting patients in the mode
hey were in at each event time. Thus the curves represent the
umulative event-free rates of each group over time, although
n the on-treatment curves, the actual membership of each
roup changed over time as a result of pacing mode crossovers.
All analyses were conducted using SAS version 8.2 (SAS
nstitute, Cary, North Carolina).
ESULTS
f 996 VVIR-randomized patients, 375 (38%) were DDDR
aced for at least part of their follow-up time in the study; 313ant. VVIR  ventricular pacing; DDDR  dual-chamber pacing.
(
s
a
D
a
D
o
r
c
l
a
F
d
T
A
F
N
W
P
N
L
P
F
P
C
P
H
H
M
P
D
C
K
P
V
A
A
*
o
i VVI
t Asso
2262 Hellkamp et al. JACC Vol. 47, No. 11, 2006
Treatment Crossovers in the MOST Study June 6, 2006:2260–631%) remained in DDDR at the last follow-up visit. Time
pent in DDDR pacing accounted for 27% of follow-up days
mong all VVIR-randomized patients (Fig. 1). Of 1,014
DDR-randomized patients, only 53 (5%) were VVIR paced
t some point, accounting for 1.5% of follow-up days among
DDR-randomized patients.
able 1. Baseline Characteristics for Patients by Randomized Pac
Baseline Characteristics*
D
(n
ge, yrs 74
emale 47%
onwhite race 16%
eight, lbs 165
rior HF 22%
YHA HF class III or IV 18%
ow ejection fraction‡ 28%
rior myocardial infarction 28%
amily history of sudden death or myocardial infarction 24%
rior angina 28%
ardiomyopathy 13%
rior revascularization 30%
ypertension 63%
ypercholesterolemia 37%
urmur of mitral regurgitation 15%
rior stroke 11%
iabetes 24%
harlson comorbidity index
0 33%
1 or 2 45%
3 or 4 15%
5 or higher 8%
arnofsky score
80–100 (normal) 69%
50–70 (some assistance needed) 27%
20–40 (hospital care required) 3%
rior supraventricular arrhythmia 54%
entricular tachycardia/fibrillation 4%
trioventricular conduction disturbance 20%
ntiarrhythmic therapy at admission 18%
Age and weight are given as median (quartiles). All other variables are given as % (n
r who spent at least one third of follow-up time in DDDR. ‡Low ejection fraction
mpression of any left ventricular dysfunction. §VVIR-crossover group different from
DDDR  dual-chamber pacing; HF  heart failure; NYHA  New York Hearigure 2. Relative risk for each event for intent-to-treat (ITT) and on-treatme
ual-chamber pacing (DDDR) versus ventricular pacing (VVIR).In several respects, VVIR-randomized patients who crossed
ver to DDDR pacing tended to be sicker than patients who
emained in VVIR: They had more prior HF, angina, hyper-
holesterolemia, and prior revascularization and were more
ikely to be on antiarrhythmic therapy at the time of hospital
dmission (all p  0.05) (Table 1). There was also a trend
ode and Crossover Status
R
14)
VVIR, No Crossover
(n  675)
VVIR, Crossover†
(n  321)
0) 75 (68, 80) 73 (67, 79)
46% (309) 52% (168)
15% (102) 13% (42)
190) 164 (136, 188) 164 (143, 190)
16% (111) 22% (72)§
13% (88) 18% (57)
25% (166) 27% (86)
24% (159) 26% (84)
21% (141) 27% (85)
25% (172) 34% (108)§
10% (67) 12% (39)
26% (175) 34% (108)§
61% (412) 61% (196)
31% (208) 41% (132)§
14% (91) 14% (45)
11% (77) 10% (31)
20% (134) 22% (70)
38% (257) 37% (118)
40% (272) 40% (128)
16% (107) 17% (54)
6% (39) 7% (21)
71% (480) 73% (232)
26% (174) 26% (983)
3% (19) 2% (5)
52% (349) 51% (165)
2% (12) 4% (12)
21% (139) 22% (70)
16% (108) 22% (70)§
ssover patients are VVIR-randomized patients who permanently crossed to DDDR
ned as ejection fraction 50% or, where ejection fraction was not measured, clinical
R-no crossover group at p  0.05.
ciation; VVIR  ventricular pacing.ing M
DD
 1,0
(67, 8
(478)
(162)
(142,
(221)
(180)
(282)
(279)
(234)
(288)
(133)
(303)
(640)
(376)
(156)
(116)
(246)
(335)
(452)
(150)
(77)
(699)
(273)
(34)
(545)
(42)
(204)
(187)
). †Cro
is defint (OT) analyses. HR (CI)  hazard ratio (95% confidence interval) for
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June 6, 2006:2260–6 Treatment Crossovers in the MOST Studyoward more New York Heart Association (NYHA) func-
ional class III or IV congestive heart failure and a family his-
ory of sudden death or myocardial infarction (both p 0.06).
On-treatment comparisons showed slightly lower hazard
atios and p values favoring DDDR versus VVIR pacing
ompared to intent-to-treat comparisons (Fig. 2).
Event-free survival curves for the primary end point of
eath or stroke and the secondary end points of HFH and
F were similar for the intent-to-treat and on-treatment
omparisons (Figs. 3 to 5).
ISCUSSION
ince the MOST results were published (1), questions have
een raised about their interpretability because of the
elatively high crossover rate. This analysis finds that the
mpact of crossovers on the trial results is negligible.
On-treatment analyses in which pacing mode is a
ime-dependent covariate, taking into account changes
rom single-chamber pacing to DDDR or vice versa,
eveal that the randomized mode comparisons may have
igure 3. Event-free rates for the primary end point (all-cause mortality or no
VIR  ventricular pacing; DDDR  dual-chamber pacing.lightly underestimated treatment effects. None of the uonsignificant tests became significant in the time-
ependent covariate models, and decreases in hazard ratio
stimates were small.
eath. The hazard ratio for death changed only from 0.95
o 0.94, which is consistent with chance when analyzing
lightly regrouped patients when no treatment effect exists.
herefore the results of the on-treatment analysis support
hose of the intent-to-treat analysis, i.e., no relationship
etween pacing mode and mortality risk. This result is
onsistent with that of another large pacing study, the
anadian Trial Of Physiologic Pacing (CTOPP) (6), which
ound no difference in mortality in a comparison of ventric-
lar versus physiologic pacing in 2,568 patients with SND
r atrioventricular block. Similarly, the UK Pacing and
ardiovascular Events (UKPACE) trial (7) found no dif-
erence in mortality among 2,021 patients with high-grade
trioventricular block randomized to dual- or single-
hamber pacing. Results in smaller trials have been mixed.
he Pacemaker Selection in the Elderly (PASE) trial (8)
ound no mortality difference in a comparison of ventric-
stroke) by pacing mode for (A) intent-to-treat and (B) on-treatment analyses.lar versus dual-chamber pacing in 407 elderly patients
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Treatment Crossovers in the MOST Study June 6, 2006:2260–6ith SND or atrioventricular block; Andersen et al. (9)
ound a difference in unadjusted but not adjusted tests in
comparison of atrial and ventricular pacing in 225
atients with SND.
troke. Strokes were a relatively rare occurrence in the
OST study, only 90 occurring during the course of the
rial. It is notable that the intent-to-treat hazard ratio was
.81, well below 1 and not much different from the hazard
atio for AF, 0.77, which was significant. With fewer stroke
vents, however, the confidence interval for the stroke
azard ratio was wide; therefore, the treatment comparison
ith respect to stroke was not significant. Thus it is not
ossible in the MOST study to determine whether there is
o underlying effect of pacing mode on the occurrence of
troke or whether an effect exists but the trial was simply
nderpowered to detect it. In the on-treatment analysis,
troke showed the largest decrease in hazard ratio of all the
nd points, from 0.81 to 0.74, with a corresponding drop in
value from 0.33 to 0.15. This raises the intriguing
ossibility that a DDDR benefit in reducing stroke does
igure 4. Event-free rates for first HFH by pacing mode for (A) intent-t
ual-chamber pacing.xist that the MOST study could not detect, and that more catients or a longer follow-up (or both) might show a
tatistically significant 20% to 25% relative risk reduction.
his would agree with Andersen et al. (9), who found a
eduction in thromboembolic events with atrial versus
entricular pacing. In another small study, Mattioli et al.
10) found a reduction in strokes with physiologic pacing in
10 patients with SND or atrioventricular block. It would,
owever, be in contrast to the other large trials: CTOPP,
hich found no stroke reduction, and UKPACE, which
ound no reduction in a composite of stroke, transient
schemic attack, or other thromboembolism with dual-
hamber pacing.
FH. There was almost no change in the hazard ratio for
FH from the intent-to-treat analysis (0.73) to the on-
reatment analysis (0.72). It is perhaps surprising that we do
ot see a large decrease with the latter analysis, because this
s an end point for which there is evidence from the MOST
tudy that a DDDR benefit exists.
Crossovers have only a minimal impact in on-
reatment comparisons of HFH when the patients who
t and (B) on-treatment analyses. VVIR  ventricular pacing; DDDR hange to the other treatment have a higher baseline risk
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June 6, 2006:2260–6 Treatment Crossovers in the MOST Studyf the event, because their higher risk cancels out some of
he benefit gained from DDDR pacing. The VVIR
atients who required crossover had a higher baseline
revalence of HF risk factors (prior HF, higher NYHA
unctional class, antiarrhythmic therapy [11]) than the
oncrossover VVIR patients and therefore a higher
aseline risk of HFH.
The significant reduction in HFH risk with dual-
hamber pacing is in contrast to the CTOPP and UKPACE
rials, which found none. In the PASE trial, the composite
nd point of death, stroke, or HFH showed a nonsignificant
p  0.07) trend toward dual-chamber benefit among
atients with SND. A large retrospective study found a
ignificant association between risk of HFH and single-
ompared with dual-chamber pacing in 11,426 pacemaker
ecipients with no prior HF (12).
trial fibrillation. Similarly, a decrease in hazard ratio
ould be expected for AF because a DDDR benefit was also
pparent in this intent-to-treat analysis, and it does show a
odest decrease from 0.77 to 0.72. Unlike HFH, there does
igure 5. Event-free rates for AF by pacing mode for (A) intent-to-tr
ual-chamber pacing.ot seem to be any imbalance in the most important AF risk iactor in the MOST study (prior supraventricular tachyar-
hythmias) between crossover and noncrossover VVIR pa-
ients. Therefore there would be no higher AF risk among
rossover patients to cancel out the DDDR benefit, and the
ecrease of 0.05 in the hazard ratio is what might reasonably
e expected.
In contrast to the mixed evidence for the other end
oints, a reduction in AF with dual-chamber pacing has
een found in almost all other trials, including the CTOPP
tudy, the PASE trial (13), and Mattioli et al. (10). Only the
KPACE trial, in which all patients had high-grade
trioventricular block, found no difference in atrial fibril-
ation.
rossovers. Hardware-randomized trials, in which im-
lanting a new device is required to change modes, typically
ave low rates of crossover from ventricular to dual-chamber
acing. In the CTOPP study the rate was 2.7% after 3 years,
nd in the UKPACE trial 3.1% after 3 years; Andersen et al.
9) reported 3.5% crossovers in long-term follow-up (mean
.5 years). In contrast, crossovers are much more common
nd (B) on-treatment analyses. VVIR  ventricular pacing; DDDR n trials in which only programming changes are required.
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Treatment Crossovers in the MOST Study June 6, 2006:2260–6he MOST study had a 31% permanent crossover rate, and
he PASE trial had 26%. Various criticisms have been made
f the latter type of trial design (14–17), in which the ease
f mode change may artificially increase the estimate of the
ate of pacemaker syndrome or other reasons for crossover
nd otherwise confound pacing mode comparison. In this
nalysis, we have determined that the rate of crossovers from
entricular to dual-chamber pacing in the MOST study did
ot, in fact, affect the interpretability of the results of the
ntent-to-treat analysis.
tudy limitations. This analysis was not prespecified in the
rial design. Although pacing mode was randomized, cross-
vers were not, so there are possible sources of bias in
n-treatment analyses. Because mode is no longer truly
andom in the on-treatment analyses, it is not possible to
mply cause and effect. However, it is important to note that
he purpose of this analysis was to supplement the intent-
o-treat results rather than to supersede them in any way.
Although we have considered pacing mode as the only
ariable that changes over time, clearly there are other
ariables that may have changed over the course of long-
erm follow-up, including comorbidities, medical therapy,
nd device-related factors. Had all of these changes been
ecorded during the trial and allowed to change over time in
he analysis, the relationships of pacing mode to events
ight have been different.
For the end points of AF and HFH, only the first
ccurrence was considered, and subsequent episodes were
either systematically recorded nor adjudicated during the
rial. It is possible that a change from VVIR to DDDR
educed the risk of subsequent episodes of AF or HFH. If
ll episodes had been considered, a more dramatic difference
ight have been seen between intent-to-treat and on-
reatment analyses.
onclusions. Although treatment crossovers accounted for
ore than 25% of follow-up time in the VVIR-randomized
roup, this did not affect study results. End point compar-
sons between randomized modes are accurate reflections of
DDR and VVIR pacing in this study population.
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